These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2713 related articles for article (PubMed ID: 16236738)
41. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119 [TBL] [Abstract][Full Text] [Related]
42. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. Russell SD; Blackwell KL; Lawrence J; Pippen JE; Roe MT; Wood F; Paton V; Holmgren E; Mahaffey KW J Clin Oncol; 2010 Jul; 28(21):3416-21. PubMed ID: 20530275 [TBL] [Abstract][Full Text] [Related]
43. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412 [TBL] [Abstract][Full Text] [Related]
44. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. Fehrenbacher L; Cecchini RS; Geyer CE; Rastogi P; Costantino JP; Atkins JN; Crown JP; Polikoff J; Boileau JF; Provencher L; Stokoe C; Moore TD; Robidoux A; Flynn PJ; Borges VF; Albain KS; Swain SM; Paik S; Mamounas EP; Wolmark N J Clin Oncol; 2020 Feb; 38(5):444-453. PubMed ID: 31821109 [TBL] [Abstract][Full Text] [Related]
45. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292 [TBL] [Abstract][Full Text] [Related]
47. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921 [TBL] [Abstract][Full Text] [Related]
48. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257 [TBL] [Abstract][Full Text] [Related]
49. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149 [TBL] [Abstract][Full Text] [Related]
50. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C; Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Sawaki M; Tokudome N; Mizuno T; Nakayama T; Taira N; Bando H; Murakami S; Yamamoto Y; Kashiwaba M; Iwata H; Uemura Y; Ohashi Y Jpn J Clin Oncol; 2011 May; 41(5):709-12. PubMed ID: 21355003 [TBL] [Abstract][Full Text] [Related]
52. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607 [TBL] [Abstract][Full Text] [Related]
53. HER2 and response to paclitaxel in node-positive breast cancer. Hayes DF; Thor AD; Dressler LG; Weaver D; Edgerton S; Cowan D; Broadwater G; Goldstein LJ; Martino S; Ingle JN; Henderson IC; Norton L; Winer EP; Hudis CA; Ellis MJ; Berry DA; N Engl J Med; 2007 Oct; 357(15):1496-506. PubMed ID: 17928597 [TBL] [Abstract][Full Text] [Related]
54. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. von Minckwitz G; Procter M; de Azambuja E; Zardavas D; Benyunes M; Viale G; Suter T; Arahmani A; Rouchet N; Clark E; Knott A; Lang I; Levy C; Yardley DA; Bines J; Gelber RD; Piccart M; Baselga J; N Engl J Med; 2017 Jul; 377(2):122-131. PubMed ID: 28581356 [TBL] [Abstract][Full Text] [Related]
55. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505 [TBL] [Abstract][Full Text] [Related]
56. Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. Lambertini M; Poggio F; Bruzzone M; Conte B; Bighin C; de Azambuja E; Giuliano M; De Laurentiis M; Cognetti F; Fabi A; Bisagni G; Durando A; Turletti A; Urracci Y; Garrone O; Puglisi F; Montemurro F; Ceppi M; Del Mastro L; Int J Cancer; 2020 Jul; 147(1):160-169. PubMed ID: 31724170 [TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice. Pernas S; Gil-Gil M; de Olza MO; Gumà A; Climent F; Petit A; Pla MJ; García-Tejedor A; López-Ojeda A; Falo C; Fernandez-Otega A; Mesia C; Pérez-Martin FJ; Urruticoechea A; Germà JR Breast Cancer Res Treat; 2012 Aug; 134(3):1161-8. PubMed ID: 22772380 [TBL] [Abstract][Full Text] [Related]
58. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience. Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556 [TBL] [Abstract][Full Text] [Related]
59. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Baselga J; Manikhas A; Cortés J; Llombart A; Roman L; Semiglazov VF; Byakhov M; Lokanatha D; Forenza S; Goldfarb RH; Matera J; Azarnia N; Hudis CA; Rozencweig M Ann Oncol; 2014 Mar; 25(3):592-598. PubMed ID: 24401928 [TBL] [Abstract][Full Text] [Related]
60. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Morris PG; Iyengar NM; Patil S; Chen C; Abbruzzi A; Lehman R; Steingart R; Oeffinger KC; Lin N; Moy B; Come SE; Winer EP; Norton L; Hudis CA; Dang CT Cancer; 2013 Nov; 119(22):3943-51. PubMed ID: 24037735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]